WAVEMAN · COMPANY

EVO · Evotec Se

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

EVO

Name: Evotec SE (EVO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Evotec SE

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001412558

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

17 funds added or opened last quarter

below 72% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 92% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

MAK Capital Fund LP disclosed a 5%+ stake (7.0%) in the last six months.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 17 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Evotec SE in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

DCF Advisers, LLC

1,079,024.0 sh

$3.0M

WCM INVESTMENT MANAGEMENT, LLC

671,884.0 sh

$1.9M

ABC ARBITRAGE SA

371,936.0 sh

$1.0M

Optiver Holding B.V.

322,153.0 sh

$902.0K

MORGAN STANLEY

205,763.0 sh

$576.1K

5%+ owners

13D = intent to influence · 13G = passive

MAK Capital Fund LP

ACTIVIST 13D · 2026-03-30

7.0%

MAK Capital One L.L.C.

ACTIVIST 13D · 2026-03-30

7.0%

Michael A. Kaufman

ACTIVIST 13D · 2026-03-30

7.0%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Nasdaq Composite Index Fund

$23.6K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2024-12	2023-12	2022-12	2021-12
GROSS PROFIT	$114.9M	$175.1M	$174.1M	$151.5M
NET INCOME	$-196.1M	$-83.9M	$-175.7M	$215.5M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE